ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1547716
This article is part of the Research TopicInnovative Approaches and Molecular Mechanisms in Cardiovascular PharmacologyView all 12 articles
Gastrodin Mitigates Aortic Valve Calcification by Inhibiting Glycolysis and Histone Lactylation Through Interfering with Valve Interstitial Cells
Provisionally accepted- 1Chongqing University, Chongqing, China
- 2Hubei University of Chinese Medicine, Wuhan, Hubei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Calcific aortic valve disease (CAVD) is the most common disease of the heart valves and is characterised by thickening, fibrosis and calcification of the aortic valve leaflets. Gastrodin, the active component of the traditional Chinese medicine Gastrodia elata Blume, has antioxidant, anti-inflammatory, anti-apoptotic and antiviral activities and is widely used in the treatment of neurological and cardiovascular diseases. Here, we report that gastrodin attenuates calcification in CAVD, but the underlying mechanism is unclear. In the present study, we investigated the molecular targets and signaling mechanisms by which gastrodin inhibits CAVD calcification. In vitro experiments such as Alizarin Red staining and In-cell western were used to evaluated the anti-calcification effect of gastrodin in the treatment of aortic valves. Transcriptome sequencing and gas chromatography-mass spectrometry analyses showed that gastrodin inhibited the glycolysis level of valvular interstitial cells (VICs). Mechanistically, gastrodin reduces the glycolysis level and lactate production of VICs by inhibiting the enzymatic activity and protein expression of PKM2. Notably, gastrodin treatment inhibited the correlation between histone lactylation H3K9la, a novel lysine-modified modality using lactate as a substrate, and the CAVD marker BMP2. The beneficial effect of gastrodin in reducing aortic valve calcification was demonstrated in vivo in high-fat fed ApoE -/-mice. In conclusion, our study shows that gastrodin exerts its anti-calcific effect by interfering with glycolysis and lactylation of VICs, demonstrating the potential of gastrodin as therapeutic agent for CAVD.
Keywords: :calcific aortic valve disease, natural product, Glycolysis, histone lactylation, Gastrodin
Received: 18 Dec 2024; Accepted: 29 May 2025.
Copyright: © 2025 Zhang, Wang, Wu, Du, Yu, Yang, Liu, Xu, Wang and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xianqiong Liu, Hubei University of Chinese Medicine, Wuhan, 430065, Hubei Province, China
Kang Xu, Hubei University of Chinese Medicine, Wuhan, 430065, Hubei Province, China
Chunli Wang, Hubei University of Chinese Medicine, Wuhan, 430065, Hubei Province, China
Fan Feng, Hubei University of Chinese Medicine, Wuhan, 430065, Hubei Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.